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Abstract
Objectives The aims of this study were to determine the
bone mineral density (BMD) in bisphosphonate-related
osteonecrosis of the jaw (BRONJ) by cone-beam computed
tomography (CBCT) measurements and to correlate these
measurements with the current stages recommended by the
American Association of Oral and Maxillofacial Surgeons
(AAOMS).
Methods Bone mineral density measurements of various
areas in 24 bisphosphonate-related osteonecrosis (BRON)
jaws were evaluated by CBCT. Another 24 age- and sex-
matched patients without any bone pathologies served as
the control group. Data acquisition was highly standardized
to ensure maximum reliability in the comparisons of BMD
measurements by CBCT.
Results Compared with the control group, the bisphospho-
nate patients had significantly higher (p B 0.01) BMDs in the
non-affected jaw areas ipsilateral and contralateral to the
BRON within the maxilla and mandible. The highest BMDs
within the BRON jaws were observed in the BRON-adjacent
areas relative to the non-affected ipsilateral and contralateral
areas. Regarding the correlation with the AAOMS stages, the
BMDs of the evaluated areas of BRONJ showed no significant
differences (p C 0.05) between the stages.
Conclusions Bisphosphonate-related bone pathologies
can be detected by CBCT and are associated with increased
BMDs, not only in clinically obvious BRONJ areas, but
also in clinically unapparent areas, suggesting a subclinical
general osteosclerosis of the jaw. The data transferability to
other CBCT devices needs to be further elucidated and
compared with multislice CT.
Keywords Bisphosphonate  Cone-beam computed
tomography  Density  Osteonecrosis  Bone mineral
density
Introduction
Over the past several years, numerous clinical and exper-
imental studies have been performed to investigate the
incidence and pathogenesis of bisphosphonate-related
osteonecrosis of the jaw (BRONJ). The research has
mainly focused on the commonly used potent nitrogen-
containing bisphosphonates, which currently play pivotal
roles in the treatment of diseases with increased bone
resorption, such as osteoporosis, antagonism of hypercal-
cemia, malignancies and osseous metastasis [1, 2]. Sup-
pression of receptor activator of nuclear factor-jB ligand
(RANKL) with subsequent reduced osteoclast activation
and bone resorption was described as the key mechanism
for the bisphosphonate effects and treatment. To date,
many hypotheses have been proposed to explain the path-
ogenesis of BRONJ. Accumulation of bisphosphonates
caused by the high bone turnover within the jaw, along
with its toxic effects, is frequently discussed [3, 4].
The common estimation of 190 million prescriptions
issued before 2007 and the increased risk from long-term
drug exposure may increase the incidence of BRONJ in the
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future [5–8]. Even though there is a low cumulative inci-
dence ranging from 0.8 to 12 %, BRONJ will emerge as a
severe side pathology in the oncologic and maxillofacial
fields [5].
Many efforts have been made to prevent this localized
bone pathology, because it is frequently associated with
invasive dento-alveolar treatment. Classifications and
treatment protocols have been introduced to support the
decision-making process and further treatment by clini-
cians. However, there is still a lack of knowledge con-
cerning the pathogenesis of this bone pathology.
Marx et al. [9] and Ruggiero et al. [10] described an
osteopetrotic bone disorder leading to avascular osteone-
crosis caused by bisphosphonate treatment. A recent in
vitro study sustained this theory by showing significantly
higher proliferation of human alveolar cells compared with
osteoblasts of the long bone [11]. Furthermore, significant
changes in the expression of soft tissue and bone matrix
proteins, such as Msx-1, RANKL and bone morphogenetic
protein (BMP) 2/4, in the periodontal tissue of BRONJ,
leading to positive bone turnover, have been described
[12]. Therefore, one can hypothesize that bisphosphonate
intake is associated with an increase in the bone mineral
density (BMD), i.e., general osteosclerosis of the jaw.
BRONJ may be associated with a general increase in the
BMD not only in clinically localized bisphosphonate-
related osteonecrosis (BRON)-adjacent areas, but also in
clinically unapparent areas, suggesting a subclinical, but
potential, risk factor. At present, there is a lack of data
focusing on BMD determination in various regions of
BRONJ and the correlation with the commonly used clin-
ical stages of the American Association of Oral and
Maxillofacial Surgeons (AAOMS).
Cone-beam computed tomography (CBCT), which uti-
lizes cone-beam geometry, flat-panel detection and three-
dimensional (3D) reconstruction algorithms, has emerged
as an important technical advancement in maxillofacial and
dental imaging [13, 14], and its usefulness for numerous
indications has been proven [15–18]. The relatively low
radiation doses with high spatial resolution and accurate
3D views allow thorough information to be obtained for the
bone dimensions and quality, e.g., the BMD [19]. Tra-
becular BMD measurements have been shown to be able to
detect slight changes in bone turnover and may potentially
be useful in the detection of early stages of bone diseases
[20]. Recent advances in CBCT techniques and software
tools for post-processing have sparked interest in evaluat-
ing this imaging modality as a potentially valuable diag-
nostic tool for the early detection of BRONJ.
To gain evidence regarding the hypothesized increase in
bone mineralization through bisphosphonate treatment, the
aims of this study were to compare the BMD measure-
ments obtained by CBCT on various areas of BRONJ and
to further correlate these measurements with the commonly
accepted stages of the AAOMS.
Patients and methods
Patients
A total of 48 patients were included in this retrospective
study, comprising 24 BRONJ patients and 24 age- and sex-
matched controls. The 24 BRONJ patients (19 females, 5
males; mean age 70.2 years; age range 46–84 years)
had histories of osteoporosis, osseous metastasis and
malignancy, and were referred to our Department of
Cranio-Maxillofacial Surgery for clinical and radiological
evaluation prior to surgery. BRONJ in the patients was
characterized and staged according to the BRONJ criteria
of the AAOMS. All specimens taken perioperatively
showed distinct histopathological aspects of BRONJ.
Exclusion criteria for the study were signs of soft and hard
tissue inflammation within the jaws, except for regions of
exposed bone. Additional exclusion criteria were radiation
therapy and disease compromising bone turnover in the
patient history. The 24 age- and sex-matched patients
(19 females, 5 males; mean age 68.0 years; age range
45–83 years) without soft or hard tissue pathologies, rele-
vant comorbid disease or medical treatment served as a
control group. All patients provided informed written
consent prior to their inclusion in this study.
CBCT
A KaVo 3-D eXam (KaVo Dental GmbH, Biberach, Ger-
many) with an amorphous silicon flat-panel detector
(20 9 25 cm) was used as the CBCT unit. The exposure
volume was set at a height of 102 mm, and the voxel size
was 0.4 mm. The scan was set at a high-frequency constant
potential of 120 kVp, and the occlusal plane of each patient
was set parallel to the floor base using ear rods and a chin
rest. The patient position was adjusted according to
alignment laser beams, and all scans were performed by a
uniquely trained team of three experienced dento-maxil-
lofacial radiographers. The calculated digital imaging and
communications in medicine data were transferred and
evaluated by the system’s software viewer (KaVo eXam
version 1.8.0.5; KaVo). The CBCT unit and its software
were regularly calibrated according to the manufacturer’s
instructions. The calibration procedure included geometric
as well as density measurements with a normalized phan-
tom material. BMD analyses in the regions of interest
(ROIs) were performed using algorithms based on the
voxel value distribution. The obtained images provided
X-ray attenuation information for specific image voxels in
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terms of bone density values (BDVs) related to the gray-
scale. These data were used to determine the density of the
scanned bone.
Measurements
The KaVo eXam version 1.8.0.5 software viewer was used
interactively in this study. Each CBCT scan was analyzed
by positioning ROIs in the anterior mandible (incisor
region), posterior mandible (molar region), anterior maxilla
(incisor region) and posterior maxilla (molar region). Three
additional ROIs were drawn in the BRON-adjacent regions
(anterior, posterior and caudal to the lesion), as indicated in
the exemplary distribution shown in a panoramic scout
view of the unit in Fig. 1. Measurements were performed
exclusively in the multi-planar view. After reorientation of
the x–y–z axis according to the axial, coronal and sagittal
planes, measurements to determine the BDVs were carried
out (Fig. 2). The sizes of the ROIs were standardized
between 30 and 40 mm2 for all measurements of the
anterior and posterior regions. The ROI sizes for the
BRON-adjacent area measurements were between 20 and
30 mm2. The authors ensured that only trabecular bone was
in the measured fields.
Statistical analysis
Statistical analyses of all data were carried out using SPSS
version 18.0 for Mac software (SPSS, Cary, NC, USA).
The measurements for the anterior and posterior regions of
one half jaw were combined into a single jaw area. Within
the BRONJ group, the areas were additionally divided
depending on the location of the clinically apparent
BRONJ into BRON ipsilateral and contralateral jaw areas.
All measurements of the osteonecrotic adjacent ROIs were
combined into one BRON-adjacent area.
A comparative analysis of the data was performed for
each group and jawbone area. The mean, standard devia-
tion, median, minimum, maximum and confidence interval
of the values were calculated for each group. The results
were analyzed using Student’s t test and analysis of vari-
ance. A significant difference was assumed if the proba-
bility value was less than 0.05.
Ethical statement
The study design met the criteria in paragraphs 4a and b of
the guidelines (version 21.5.2010) of the Cantonal Ethics
Committee of Zurich, and was therefore exempt from
Institutional Review Board approval. The study design
thereby fulfilled the guidelines of the Declaration of Hel-
sinki concerning Ethical Principles for Medical Research
Involving Human Subjects.
Results
In this study, 24 patients with BRONJ (19 females, 5
males; mean age 70.2 years; age range 46–84 years) and
24 patients without any bone pathology (19 females, 5
males; mean age 68.0 years; age range 45–83 years) were
examined. The demographic data (sex, age, disease, type of
Fig. 1 Panoramic scout view of the CBCT unit showing an
exemplary distribution of the ROIs. The anterior and posterior ROIs
within the mandible are marked by white squares. The anterior and
posterior regions of the right hemi-mandible were combined as one
jaw area (BRON ipsilateral area), while the areas of the left hemi-
mandible were combined as the BRON contralateral area. The ROIs
adjacent to the BRON (anterior, posterior and caudal to the
demarcation line) marked by black squares were combined into one
BRON-adjacent area
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bisphosphonates, duration of treatment, trauma in history,
AAOMS stage) are shown in Table 1.
Overall, the bisphosphonate patients with BRON had
significantly higher (p B 0.01) mean BMDs in the maxilla
and mandible within the ipsilateral and contralateral jaw
areas compared with the control group (Figs. 3, 4).
Significantly higher BMDs in the BRON-adjacent areas
compared with the clinically affected BRON ipsilateral,
contralateral and control jaw areas could be measured
(Figs. 3, 4, 5, 6). Descriptive data for the evaluated groups
and areas are shown in Table 2.
The BMDs of the evaluated areas in BRONJ divided
into stage II and stage I according to the AAOMS showed
no significant differences (p C 0.05). No statistical con-
clusion was reached for stage III disease because of the low
number of patients with this stage in the examined group.
Fig. 2 ROI with the corresponding measured field marked by a red square adjusted to the axial, coronal and sagittal planes for 3D BMD
evaluation (color figure online)
Table 1 Demographic data for the patients with BRONJ
Sex Age (years) Disease Bisphosphonate Duration of treatment
before BRONJ (months)
History of trauma Stagesa
F 68 Breast cancer Zoledronate 60 Tooth extraction 3
F 75 Thyroid cancer Zoledronate 36 Tooth extraction 2
F 85 Breast cancer Zoledronate 48 Tooth extraction 3
F 57 Breast cancer Zoledronate 48 – 1
F 77 Breast cancer Zoledronate 8 Tooth extraction 3
F 80 Breast cancer Zoledronate 9 Tooth extraction 1
F 69 Breast cancer Zoledronate 22 Explantation 2
F 67 Osteoporosis Zoledronate Tooth extraction 1
F 67 Breast cancer Zoledronate 34 – 2
F 71 Breast cancer Zoledronate 24 Tooth extraction 2
M 67 Renal cell cancer Zoledronate Explantation 1
F 67 Osteoporosis Alendronate 36 Tooth extraction 2
F 75 Osteoporosis Alendronate 120 Tooth extraction 2
F 64 Breast cancer Zoledronate 9 Tooth extraction 2
F 83 Osteoporosis Ibandronate 12 Poorly fitting denture 2
F 46 Melanoma Zoledronate – 2
F 79 Osteoporosis Ibandronate 18 Tooth extraction 2
F 61 Malignant mesothelioma Zoledronate 18 Tooth extraction 2
F 75 Osteoporosis Aledronate 36 – 2
M 70 Multiple myeloma Zoledronate Implantation 2
M 65 Multiple myeloma Zoledronate 36 – 3
F 60 Breast cancer Zoledronate Tooth extraction 2
M 79 Prostate cancer Zoledronate 48 – 1
F 85 Osteoporosis Pamidronate 36 Tooth extraction 2
a According to the stages of the AAOMS
–, No trauma in the history
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Discussion
During the past decade, many attempts have been made to
elucidate the pathogenesis of BRONJ and its incidence in
the general population [2, 11, 12].
Recent in vitro studies have indicated that bisphospho-
nates potently inhibit bone resorption by suppressing the
recruitment and activity of osteoclasts, and even by
inducing apoptosis, leading to a general decrease in bone
resorption [21–23]. Beyond their anti-resorptive properties,
nitrogen-bisphosphonates enhance the proliferation of
osteoprogenitor cells and osteoblasts, and upregulate BMP-2,
collagen type II and osteocalcin, thereby pushing the bone
turnover toward increases in bone matrix formation and
mineralization [11, 24–26].
In accordance with the current clinical and molecular
findings, the aims of this study were to evaluate the BMDs
within various jaw areas of BRON patients and to com-
pare these measurements with an age- and sex-matched
control group. In the current literature, one can find
several radiological studies using CBCT technology for
BMD determinations to address various scientific ques-
tions [27, 28].
Owing to the low-dose high-spatial-resolution visuali-
zation of high-contrast structures and accurate 3D views,
CBCT imaging permits quantitative and qualitative eval-
uations of osseous structures. For these reasons, as well as
socioeconomic costs, especially under the premise of pro-
spective regular follow-ups, the authors chose CBCT
technology for their BMD evaluations.
The results of the present study revealed significantly
higher BDVs in all evaluated areas in patients with BRONJ
compared with those in the control group. Significant dif-
ferences in the BMDs within the BRON ipsilateral jaw
areas compared with the contralateral areas were also
found. As a consequence, CBCT technology may allow the
detection of bisphosphonate-related osseous changes and
differences within the jaw.
The areas adjacent to the osteonecrotic sites showed
significantly higher BMDs than the ipsilateral or contra-
lateral jaw areas. Exposed bone and delayed wound healing
with a nearly obligate involvement of the oral microflora
(e.g. Actinomyces) will lead to the development of an
inflammatory process and further trigger osteosclerotic
bone remodeling (condensing osteitis). The latter factors
and impaired vascular nutrition may considerably support
the hypothesis of avascular osteonecrosis within the jaws
[29, 30].
BRONJ may be associated with an increase in BMD not
solely in clinically obvious BRON-adjacent areas, but also
in clinically unapparent areas, suggesting a subclinical
general osteosclerosis of the jaw.
In this study, the authors were unable to detect any
significant differences in the BMDs of BRONJ patients
between AAOMS stage I and stage II [5]. These findings
further underline the heterogeneous clinical picture of this
bone pathology. However, coherence between the BMDs
and the AAOMS stages is desirable to allow prediction of
the genesis of BRONJ. The AAOMS stages represent the
course of osteonecrosis progression and complications, but
do not consider the general osseous changes within the
Fig. 3 Box-plot diagram representing the bone density distribution
within the maxilla of BRONJ patients (ipsilateral, contralateral and
adjacent areas) and the corresponding control group
Fig. 4 Box-plot diagram representing the bone density distribution
within the mandible of BRONJ patients (ipsilateral, contralateral and
adjacent areas) and the corresponding control group
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entire jaw. Therefore, it may be interesting to include BMD
measurements obtained by CBCT in the staging of BRONJ,
since osteosclerosis may be a potential risk factor for an
early stage of the development of this disease. Conse-
quently, clinicians should be aware that the clinical picture
of a bisphosphonate-related osteonecrotic lesion may pos-
sibly only represent the tip of the iceberg. Hence, further
studies are necessary to implement BMD measurements in
the early diagnosis of bisphosphonate-related osseous
changes.
There are limitations to this study. First, a rather small
sample size was investigated. Further studies with larger
cohorts including various AAOMS stages as well as an
additional group with patients under bisphosphonate
treatment without clinically apparent BRONJ are required.
Second, CBCT bone density measurements may need to be
regarded with caution, since this modality does not yield
equally robust bone density measurements compared with
established multi-detector CT units. The beam geometry,
artifacts (metal implants), imaging parameters and object
positioning [31] are known to significantly influence
attenuation measurements. Nevertheless, this study design
included regular calibration of the CBCT unit. Identical
patient positioning, and homogeneous reconstruction
algorithms and data acquisition were used in all subjects.
Moreover, based on our experience and other studies, a low
variance of BDVs occurs in healthy patients [32, 33].
Despite the difficulties in measuring the BDVs, we have
shown that the performed technique was sufficient to detect
bone pathologies, i.e., bisphosphonate-associated bone
Fig. 5 Exemplary CBCT images of a 70-year-old woman treated
with zoledronate for 2 years with a history of metastatic breast cancer.
Axial, coronal, sagittal and panoramic scout views showing BRON
(red arrows) and perspicuous diffuse mandibular osteosclerosis
(green arrows) are shown (color figure online)
Fig. 6 Exemplary CBCT images of a 75-year-old woman treated
with zoledronate for 2.5 years with a history of thyroid cancer and
bone metastasis. Axial, coronal, sagittal and panoramic scout views
showing marked BRON (red arrows) and the corresponding osteo-
sclerosis (green arrows) affecting the maxilla are presented (color
figure online)
Table 2 Descriptive analyses of the BDVs of the BRONJ (ipsilateral, contralateral and adjacent areas) and control groups
Group Jaw Region Mean SD Median Minimum Maximum 95 % CI
Bisphosphonate Maxilla Ipsilateral 600.93 174.87 659.5 273.67 864.33 475.83–726.03
Maxilla Contralateral 360.0 219.48 336.3 29.66 770.0 202.99–517.00
Maxilla Control 246.14 122.34 230.16 48.66 630.66 221.87–270.42
Maxilla Adjacent 748.13 260.14 740.0 249.3 1132.0 604.07–892.19
Mandible Ipsilateral 762.52 299.64 735.50 256.66 1469.66 666.69–858.35
Mandible Contralateral 581.42 280.11 500.0 162.33 1169.0 486.64–676.20
Mandible Control 388.61 178.32 387.50 25.00 787.66 353.23–424.00
Mandible Adjacent 1162.85 165.84 1176.66 828.33 1473.66 1118.84–1206.85
SD Standard deviation, CI confidence interval
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sclerosis versus healthy bone. A systematic evaluation of
the stability of BDVs in CBCT and their transferability to
other devices lies beyond the scope of this study, but
should be addressed in future studies.
Further studies will hopefully be able to establish a
radiological classification for BRONJ. This should ideally
correspond with the clinical stages and provide clinicians
with reliable data about the stage of the disease. For early
detection of BRONJ and BRONJ risk evaluation in par-
ticular, this classification should be based on CBCT as the
3D imaging technology that is most commonly used in
dental surroundings.
Bisphosphonate-related bone pathologies can be detected
by CBCT and are associated with increases in the BMD not
only in clinically obvious BRONJ, but also in clinically
unapparent areas, suggesting a subclinical general osteoscle-
rosis of the jaw. The BDVs obtained by the CBCT device
allowed reliable comparisons within this study population
owing to the standardized data acquisition. The data transfer-
ability to other CBCT devices needs to be further elucidated.
Conflict of interest The authors declare that they have no conflict
of interest.
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